Education
About Us
Working with TipRanks
Follow Us
Mustang Bio Inc (MBIO)
NASDAQ:MBIO
MBIO Stock Chart & Stats
$1.09
-$0.01(-4.59%)
At close: 4:00 PM EST
$1.09
-$0.01(-4.59%)
Day’s Range― - ―
52-Week Range$0.53 - $7.00
Previous CloseN/A
Volume2.68M
Average Volume (3M)94.14K
Market Cap
$6.76M
Enterprise Value-$12.02M
Total Cash (Recent Filing)$18.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,453,701
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-14.00
Price to Sales (P/S)0.00
P/FCF Ratio-4.75
Enterprise Value/Market Cap-1.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit293.19
Enterprise Value/Ebitda5.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet (no Debt)The company reports zero reported debt in the trailing twelve months and a recovery of equity to roughly $9.8M from negative levels. This recapitalization materially improves solvency and financial flexibility, reducing near-term default risk and supporting continued clinical investment.
Sharply Reduced Net LossesA multi-year decline in annual net losses shows successful cost reduction and program prioritization. Narrowing losses lengthen runway per financing round and indicate management can slow burn while advancing key programs, lowering dilutive financing needs over the medium term.
Equity Plans Expand Talent RetentionApproval to expand employee equity and incentive plans strengthens the company’s ability to attract and retain specialized scientific and clinical staff. For a clinical-stage biotech, sustained access to talent is a durable operational advantage that supports trial execution and program continuity.
Bears Say
Pre-revenue Business ModelMustang remains essentially pre-revenue, meaning it lacks product-derived cash flows to fund operations. This structural reliance on capital markets or partners increases execution risk over the next several months and constrains self-funded expansion of clinical programs.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow requires ongoing external financing to sustain R&D and trials. Although burn has improved, continued outflows create funding dependency that can force dilution, program delays, or reprioritization if capital markets tighten.
Balance-sheet Volatility And Financing RiskHistorical swings from high leverage to recent recapitalization indicate volatility in funding access. Such variability signals refinancing and dilution risk during adverse markets, which is a structural constraint on long-term program funding and strategic optionality.
Mustang Bio News
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.53 and its highest was $7.00 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Mustang Bio Inc’s market cap is $6.76M.
When is Mustang Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mustang Bio Inc’s earnings last quarter?
Currently, no data Available
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 6,453,701 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Silexion Therapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
8.35% Insiders
0.97% Mutual Funds
1.35% Other Institutional Investors
88.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---